Thunes Launches Cross-Border Payouts Across Six New Middle East Markets

Members of Thunes' Direct Global Network gain faster, more transparent access to bank accounts, mobile wallets, and cash pickup locations across Bahrain, Lebanon, Oman, South Yemen, Syria and the UAE

RIYADH, Saudi Arabia, Sept. 14, 2026 /PRNewswire/ -- Thunes, the Smart Superhighway to move money around the world, today announced a major expansion of its Direct Global Network across the Middle East. The expansion introduces new payout services into six key markets: the Kingdom of Bahrain, Lebanon, the Sultanate of Oman, South Yemen, Syria and the United Arab Emirates (UAE).

This move significantly enhances Thunes' cross-border infrastructure in the region, delivering faster, highly transparent payment solutions for Members of Thunes' Direct Global Network. Members can now process payouts to millions of bank accounts, mobile wallets, and cash pickup locations in local currencies throughout the region, either through direct API integration with Thunes or by leveraging existing Swift connectivity.

The regional rollout builds on Thunes' expansion of real-time payments across the Kingdom of Saudi Arabia in September 2025 and targets diverse economic needs across the Middle East:

- Powering Digital Economies: In Bahrain, where the non-oil sector contributed 85% of real GDP in 2025, Thunes supports direct bank payouts aligned with the nation's National Digital Economy Strategy. In Oman, bank account payouts support the digital transformation goals of Oman Vision 2040 alongside projected GDP growth of 4% in 2026.

- Fueling Enterprise and Consumer Growth: In the UAE, a primary regional payments hub driven by the National Payment Systems Strategy (NPSS), Thunes now supports bank account payouts for both consumers and enterprises.

- Delivering Vital Remittance Lifelines: In markets relying on remittance flows for economic resilience and recovery, Thunes provides critical access points:

- - Lebanon: Supporting mobile wallet payouts in a market receiving roughly $7 billion per year in remittances.

- South Yemen: Enabling bank and cash pickup payouts where remittances represent over 38% of its total GDP, ranking among the top three most remittance-dependent nations globally.

- Syria: Introducing payouts to cash pickup locations, providing reliable financial access amid broader efforts to rebuild the local banking system.

Chloé Mayenobe, Deputy CEO at Thunes, said: "Launching new payout capabilities across the Middle East unlocks significant value for our Members and their end-users. These markets are deeply committed to digital innovation and financial inclusion. Thunes is proud to provide the infrastructure that empowers businesses and individuals to participate seamlessly in international commerce and the broader global economy."

With this expansion, Thunes reinforces its position as a leading provider of global money movement. The solutions leverage Thunes' in-house SmartX Treasury System for AI-driven forecasting and real-time liquidity management, and its Fortress Compliance Platform, which benefits from over 50 licences worldwide, ensuring that every payment is executed with the highest levels of security, compliance and operational efficiency.

About Thunes:

For more information, visit: https://www.thunes.com.

SOURCE Thunes

Share this article

DAVION HEALTHCARE £30 MILLION SENIOR SECURED BOND ADMITTED TO TRADING ON VIENNA MTF

Financing provides dedicated capital to support acquisition-led growth

DUBLIN, Sept. 14, 2026 /PRNewswire/ -- Davion Healthcare Plc ("Davion" or the "Company") is pleased to announce that the £30 million senior secured bond issued by its financing subsidiary, Davion Healthcare Finance Ltd, has been admitted to trading on the Vienna MTF, operated by the Vienna Stock Exchange (Wiener Börse AG).

The five-year bond, which commenced in August 2026, carries a fixed annual coupon of 10.5% and provides Davion with a dedicated source of capital to support the Group's acquisition strategy.

The proceeds will be made available to companies within the Davion Group to fund the acquisition of healthcare businesses and assets. Davion is targeting opportunities across medical devices, diagnostics, medical distribution, healthcare technology and healthcare services, with a particular focus on established, cash-generative businesses that can contribute earnings to the Group and provide a platform for further growth.

The financing will provide Davion with additional capacity to pursue acquisitions as the Group looks to expand its portfolio of products and businesses and build its international distribution network.

Under the structure of the bond, proceeds are deployed on an acquisition-by-acquisition basis through Davion Healthcare Finance Ltd, with security granted over the relevant assets acquired using those proceeds.

Key Bond Terms

- Issuer: Davion Healthcare Finance Ltd

- Principal amount: Up to £30 million

- Ranking: Senior secured

- Term: Five years

- Commencement: August 2026

- Annual coupon: 10.5% fixed

- Trading venue: Vienna MTF, operated by Wiener Börse AG

- ISIN: GB00BTH2SB89

- Denomination: £100,000

Davion Healthcare Finance Ltd was established as the dedicated financing subsidiary of Davion Healthcare Plc to raise and deploy capital across the Group. The admission of the bond to trading provides Davion with an additional source of acquisition finance alongside its wider corporate funding plans.

Jack Kaye, Chief Executive Officer of Davion Healthcare Plc, commented:

"The admission of our £30 million bond to the Vienna MTF gives Davion the capital to pursue the acquisition opportunities we are already evaluating across the healthcare sector.

"We are looking for established, cash-generative businesses that can contribute earnings to the Group from day one, while adding products, customers and distribution capabilities. We have a number of opportunities under review and will remain disciplined about what we acquire and the price we pay.

"Our ambition is to build a larger and more diversified international healthcare business, combining our own products with established operating businesses and distribution networks. This financing gives us the capacity to accelerate that process."

Contacts

Media Enquiries:

[email protected]

For more information please visit:

https://www.davionhealthcare.com/

About Davion Healthcare Plc

Davion Healthcare Plc is an Irish public limited company focused on the development and commercialisation of healthcare technologies and products.

The Company is developing its international commercial and distribution capabilities alongside an acquisition strategy focused on established healthcare businesses, as it seeks to build a larger and more diversified international healthcare group.

Important Notice

This announcement is for information purposes only and does not constitute, and should not be construed as, an offer to sell or a solicitation of an offer to purchase or subscribe for any securities in any jurisdiction. Admission of the bonds to trading on the Vienna MTF should not be interpreted as confirmation that the full £30 million principal amount has been subscribed, placed or funded.

The bonds are senior secured obligations of Davion Healthcare Finance Ltd. Full details of the security arrangements, ranking and rights attaching to the bonds are contained in the applicable bond and security documentation. The Vienna MTF is a multilateral trading facility operated by Wiener Börse AG and is not an EU regulated market.

FORWARD LOOKING STATEMENTS

This announcement contains forward-looking statements within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, those identified by words such as "believes," "will," "expects," "anticipates," "estimates," "intends," "plans," "targets," "projects" and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in these forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, the results of product evaluations, studies, regulatory reviews and commercial adoption and/or other studies, clinical trials, the challenges inherent in new product development initiatives, the impact of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, and other risks discussed from time to time in our filings with the Securities and Exchange Commission. We undertake no obligation to update any forward-looking statements, or any information contained in this press release or in other public disclosures, at any time. Finally, the investing public is reminded that only announcements or information about Davion Healthcare Plc disseminated by the Company and bearing its name are considered official.

SOURCE DAVION HEALTHCARE PLC

Share this article

Intuitive announces expanded indication for da Vinci SP in Europe

CE mark for transvaginal gynecologic procedures expands SP's applications

AUBONNE, Switzerland, Sept. 14, 2026 /PRNewswire/ -- Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced CE mark approval for the indication of transvaginal gynecologic procedures for the da Vinci SP (Single Port) surgical system – marking a world's-first indication for the SP system.

This approval expands da Vinci SP's CE-marked applications in Europe, which currently include endoscopic abdominopelvic, thoracoscopic, transoral otolaryngology, transanal colorectal, and breast surgical procedures.

"Building on the strong adoption of da Vinci SP in women's health, this approval is a meaningful step forward, not just as a regulatory milestone, but because it expands access to less invasive options for women across Europe and opens the door to potentially better recovery experiences and outcomes," said Dirk Barten, Intuitive commercial president for Europe.

The da Vinci SP system enables surgeons to perform procedures through a single incision or natural orifice, offering enhanced visualization and precision in narrow or deep anatomical spaces. Through a single-entry point, surgeons can control up to three multi-jointed instruments and a fully articulating 3DHD endoscope, enabling access to complex anatomy with minimal disruption to surrounding tissue.

"Transvaginal procedures expand the natural orifice surgery portfolio of the da Vinci SP System, which to this day includes successful transoral and transanal procedures," said Tilman Schlick, vice president, medical affairs & medical officer at Intuitive in Europe. "These less invasive, scarless surgery approaches have the potential to shorten recovery times and enhance patients' experience as they return to their daily lives. As we continue to innovate across our platforms, we remain focused on helping more patients access the benefits of minimally invasive care."

A growing body of evidence, including more than 1,000 peer-reviewed publications, supports the safety, efficacy, and patient outcomes associated with the da Vinci SP system. Da Vinci SP is also approved for use in the US, Japan, and Korea for a range of procedures spanning multiple surgical disciplines.

Images

Images accompanying this announcement are available here.

About Intuitive

Intuitive (NASDAQ:ISRG), headquartered in Sunnyvale, California, with European headquarters in Aubonne, Switzerland, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical system and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where disease is identified early and treated quickly, so that patients can get back to what matters most.

About da Vinci Surgical Systems

There are several models of the da Vinci surgical system. The da Vinci surgical systems are designed to help surgeons perform minimally invasive surgery and offer surgeons high-definition 3D vision, a magnified view, and robotic and computer assistance. They use specialized instrumentation, including a miniaturized surgical camera and wristed instruments (i.e., scissors, scalpels, and forceps) that are designed to help with precise dissection and reconstruction deep inside the body.

For more information, please visit the company's website at www.intuitive.com/en-gb

This material may contain estimates and forecasts from which actual results may differ. Some products, features or technologies may not be available in all countries. Please contact your local Intuitive representative for product availability in your region. Refer to the product specific User Manual for indications, contraindications, warnings and other product information.

© 2026 Intuitive Surgical Operations, Inc. All rights reserved. Product and brand names/logos, including Intuitive, da Vinci, and Ion, are trademarks or registered trademarks of Intuitive Surgical or their respective owner. See intuitive.com/trademarks.

Share this article

Collaboration Leverages Apex's 'Factory X' Model to Accelerate Elveo's D2D Time to Market

WASHINGTON, Sept. 14, 2026 /PRNewswire/ -- Elveo Mobile, the company that delivers mobile connectivity and elevated intelligence for a planet on the move, and Apex, The Spacecraft Platform Company, today announced a partnership to establish a dedicated spacecraft factory that will scale the global supply chain for the Elveo-designed direct-to-device (D2D) constellation. The partnership enables Elveo to leverage Apex's Factory X model to rapidly stand up its first satellite production facility in the U.S. and build the technical expertise needed to manufacture globally at scale.

As a vertically integrated partner, Apex will bring proven spacecraft platforms and expertise in high-rate production to equip Elveo with the capabilities it needs to operationalize its own production facility. Elveo will use this blueprint to expand its manufacturing facilities into Europe and Asia with regional partners, building a truly global supply chain for its low-Earth orbit (LEO) network.

"As a leading manufacturer of next-generation spacecraft, Apex is helping us establish vertically integrated production and scale our supply chain, giving us an innovative and capital-efficient path to build our fleet," said Ramu Potarazu, Chief Executive Officer, Elveo. "This partnership not only puts us in control of our own development destiny and cost structure but also allows us to create high-tech economic opportunities internationally with partners."

"Working with Elveo is a perfect example of how Apex's model can help accelerate proliferated LEO constellation deployments," said Ian Cinnamon, Co-Founder and Chief Executive Officer, Apex. "By partnering to stand up a dedicated production facility, we're leveraging Apex's deep expertise in mass manufacturing spacecraft platforms to deploy Elveo's constellation years ahead of traditional bus supplier timelines."

Elveo's network will feature patented satellite technology, compliant with 3GPP non-terrestrial networks (NTN) standards. Elveo's payload includes advanced on-board processing and networking, enabling the network to rapidly adapt, iterate, and grow to meet mobile network operators' (MNOs) evolving needs.

About Elveo

Elveo is the premier non-terrestrial mobile connectivity company, delivering elevated intelligence for a planet on the move. Elveo offers reliable, next-generation connectivity directly from satellites to smartphones, IoT devices and machines worldwide. Elveo is a globally inclusive company that offers mobile network operators and partners a resilient, always-on next-generation network to connect their customers across enterprise, government and humanitarian sectors. For more information, visit elveo.com.

About Apex

Apex, The Spacecraft Platform Company, is the leading manufacturer of productized, configurable satellite platforms for commercial and national security missions. Founded in 2022 by Ian Cinnamon and Max Benassi, Apex mass-manufactures standardized spacecraft that deliver the reliability, scale, and economics that today's proliferated constellations require.

Apex platforms are operational in orbit today, with serial production ramping to 200 buses per year at Apex's high-rate manufacturing facility in Los Angeles, California. Tier 1 U.S. primes and commercial operators worldwide have selected the company's Aries, Nova, and Comet product lines to support critical missions, from next-generation commercial constellations to resilient national security architectures.

Media contacts

Elveo, Marie Knowles, [email protected]

Apex, Neil Presicci, [email protected]

SOURCE Elveo Mobile

Share this article

Antengene Publishes Preclinical Research Paper on CD73 Small Molecule Inhibitor ATG-037 Combined with Selinexor in Cancer Gene Therapy

SHANGHAI and HONG KONG, Sept. 14, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune diseases, solid tumors and hematological malignancies indications, today announced that a preclinical research paper evaluating the combination of ATG-037 (CD73 Small Molecule Inhibitor) and selinexor for the treatment of multiple myeloma (MM), conducted in collaboration with the Department of Hematology at Peking University Third Hospital, has been published in Cancer Gene Therapy, an international SCI journal under Springer Nature.

Details of the Paper

Title: CD73 inhibitor enhances the antitumor activity of selinexor in multiple myeloma by restoring the activation of CD8+ T cells

Journal: Cancer Gene Therapy

DOI: 10.1038/s41417-026-01078-9

Study Design:

The research team first analyzed CD73 expression across multiple tumor cell lines following selinexor treatment, then tested the combination in vivo using a J558-inoculated BALB/c mouse model, with mice divided into a vehicle group, an ATG-037 monotherapy group, a selinexor monotherapy group and a combination-therapy group. Single-cell RNA sequencing was used to characterize immune cell subtypes and tumor-immune crosstalk, immunofluorescence staining was performed on tumor tissue, and a co-culture model of CD8+ T cells and multiple myeloma cell lines was established to confirm the mechanism behind the combination's antitumor effect.

Key Findings:

Selinexor treatment was found to upregulate CD73 expression in the majority of tumors, a resistance-associated mechanism that the combination approach was designed to counter. In the mouse model, the combination therapy suppressed tumor growth with an inhibition rate of 62%, compared with 31% for ATG-037 monotherapy and 43% for selinexor monotherapy. Single-cell RNA sequencing showed that the combination synergistically potentiated CD8+ T cell activation by enhancing the interaction between CD8+ T cells and Enpp1+ cells via the CD80–CD28 signaling pathway, and the resulting increase in CD8+ T cell infiltration into tumor tissue was confirmed by immunofluorescence staining. In co-culture experiments, CD73 inhibition was shown to strengthen selinexor-mediated tumor cell killing by activating CD8+ T cells, with significantly elevated levels of Granzyme B (P=0.0252) and IFN-γ (P=0.0067) observed in the combination group.

Conclusion:

The study highlights the synergistic potential of combining selinexor with a CD73 inhibitor for enhancing CD8+ T cell-mediated tumor cytotoxicity in MM. Selinexor therapy upregulates CD73 in the TME, driving adenosine accumulation and an immunosuppressive state. Combined use of ATG-037 blocks this immunosuppressive feedback loop via suppression of CD73-dependent adenosine synthesis, restoring CD8+ T cell activation and proliferation while enhancing T cell cytotoxicity through activation of the CD80-CD28 costimulatory axis. These findings establish a novel, clinically feasible therapeutic paradigm for addressing drug resistance and refractory MM.

About Antengene

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) is a global, R&D-driven, commercial-stage biotech company focused on developing first-in-class/best-in-class therapeutics for diseases with significant unmet medical needs. Its pipeline spans from preclinical to commercial stages, with key investigational candidates including ATG-022 (CLDN18.2 ADC), ATG-037 (oral CD73 inhibitor), ATG-101 (PD-L1 x 4-1BB bispecific antibody), ATG-125 (B7-H3 × PD-L1 bispecific ADC), ATG-207 (αCD3-TGF-β bifunctional fusion protein), as well as T cell engager (TCE) programs developed using Antengene's proprietary AnTenGager® platform.

AnTenGager®, is Antengene's proprietary TCE 2.0 platform, featuring "2+1" bivalent binding for low expressing targets, steric hindrance masking, and proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune diseases, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for B cell-related autoimmune diseases; partnered with UCB), CDH6 x CD3 (ATG-106 for ovarian cancer and kidney cancer; partnered with K2 Therapeutics established by MPM BioImpact), ALPPL2 x CD3 (ATG-112 for gynecological tumors, digestive system malignancies, bladder cancer and NSCLC), LY6G6D x CD3 (ATG-110 for microsatellite-stable colorectal cancer), GPRC5D x CD3 (ATG-021 for multiple myeloma), LILRB4 x CD3 (ATG-102 for acute myeloid leukemia and chronic myelomonocytic leukemia) and FLT3 x CD3 (ATG-107 for acute myeloid leukemia).

To date, Antengene has obtained 34 investigational new drug (IND) approvals in the U.S. and Asia, and obtained new drug application (NDA) approvals in 10 Asia Pacific markets. Its lead commercial asset, XPOVIO® (selinexor), is approved in the Mainland of China, Taiwan China, Hong Kong China, Macau China, South Korea, Singapore, Malaysia, Thailand, Indonesia and Australia, and has been included in the national insurance schemes in five of these markets (Mainland of China, Taiwan China, Australia, South Korea and Singapore).

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, please see the other risks and uncertainties described in the Company's Annual Report for the year ended December 31, 2025, and the documents subsequently submitted to the Hong Kong Stock Exchange.

For more information, please contact:

PR / IR Contacts: 

Peter Qian

E-mail: [email protected]  

BD Contacts:

Ariel Guo

E-mail: [email protected] 

SOURCE Antengene Corporation Limited

Share this article

The first official certification for MCP validates builders' understanding of MCP architecture, security, and implementation as adoption of the protocol grows

- The Model Context Protocol Associate (MCPA) is a new foundational, vendor-neutral certification validating engineering and platform builders' understanding of the Model Context Protocol (MCP) concepts, architecture, and implementation considerations.

- The exam covers five domains: MCP Fundamentals, Architecture & Components, Interactions & Execution, Security & Governance, and Use Cases & Ecosystem.

- The MCPA is the first official certification validating MCP knowledge, and the first certification launched by the Agentic AI Foundation.

SAN FRANCISCO, Sept. 14, 2026 /PRNewswire/ -- The Agentic AI Foundation (AAIF), the neutral home where the agentic stack is being built, announced the Model Context Protocol Associate (MCPA) – a new vendor-neutral credential aligned with emerging AI engineering, platform engineering, and AI governance roles, as the community convenes in Amsterdam for AGNTCon + MCPCon Europe this week.

Connecting AI models to the tools and services they need has become a critical part of building agentic systems, and MCP has become the standard for enabling those connections. MCP's usage has grown at an astonishing rate. Across MCP's Tier 1 SDKs, monthly downloads are approaching half a billion, with both the TypeScript and Python SDKs surpassing 1 billion downloads total. Usage in production is climbing just as fast. MCP tool calls from ChatGPT users reached 98 times their January level by August, and Resend passed one million MCP calls in a single month. That scale is exactly why a common way to validate MCP expertise is needed. The MCPA provides engineers, platform teams, and AI governance professionals a way to demonstrate their understanding of how the protocol works, how its components interact, and how to apply it responsibly.

"We built MCP so developers could rely on one open protocol instead of writing custom integrations for every system. Since then, it has grown exponentially. Giving developers the option to earn a certification in MCP will formalize a shared understanding of how the protocol works, while ensuring this expanding ecosystem continues to operate smoothly," said David Soria Parra, co-creator and lead maintainer of MCP.

The MCPA is a 120-minute, online, proctored, multiple-choice exam covering five domains: MCP Fundamentals (16%), Architecture & Components (14%), Interactions & Execution (26%), Security & Governance (24%), and Use Cases & Ecosystem (20%). Candidates are tested on MCP hosts, clients, servers, and tools; message flow and protocol primitives; trust boundaries, permissions, and risk controls; and how MCP is applied across real-world agentic deployments. The certification is aligned with the latest MCP specification release, 2026-07-28, and is recommended for candidates who understand the internals of the MCP and are comfortable reasoning about how the protocol works and how its components communicate.

"MCP has quickly become the standard for connecting AI agents to external systems. As organizations increasingly adopt agentic AI, they need developers who understand how those connections work and how to implement them responsibly, including the permissions and trust boundaries involved. With the MCPA, developers can demonstrate that knowledge through an official certification, giving employers a shared benchmark for assessing the skills required for modern software development," said Angie Jones, Vice President of Developer Experience, Agentic AI Foundation.

Now Available

The MCPA is live and open for enrollment. Individuals attending AGNTCon + MCPCon Europe in Amsterdam this week can enroll now at a 20% discount, and the same discount is available to those registering for AGNTCon + MCPCon North America, taking place October 22–23, 2026 in San Jose, California.

More information about the MCPA, including exam domains, prerequisites, and candidate resources, is available at training.linuxfoundation.org/certification/model-context-protocol-associate-mcpa.

About the Agentic AI Foundation

The Agentic AI Foundation (AAIF) is the neutral home where the agentic stack is being built. With founding projects including MCP, A2A, AGENTS.md, goose, agentgateway, and Agent Router, AAIF governs the core standards and protocols that enable agents to operate interoperably across platforms. Through transparent governance and broad industry participation, AAIF is driving adoption and ensuring agentic AI infrastructure evolves openly, predictably, and at production scale. For more information, please visit aaif.io.

Media Contact

Sarah Zonouzi

Agentic AI Foundation

[email protected]

SOURCE Agentic AI Foundation

Share this article

SLI's asset financing model, proven across other asset classes, such as transportation and energy, now accelerates deployment of orbital infrastructure

PASADENA, Calif., Sept. 14, 2026 /PRNewswire/ -- Sophia Space today announced a $300 million financing framework with aerospace leasing specialist, SLI, for a planned 10-satellite high-performance edge computing constellation, bringing proven financing models used to scale aviation, energy, maritime, rail, and telecommunications, into this next phase of orbital computing. Under the arrangement, SLI will purchase the satellites from Sophia and lease them to the end-users on the basis of fixed monthly or quarterly payments.

Once deployed, the constellation would deliver aggregate computing capacity equivalent to 240 state-of-the-art edge servers, while allowing Sophia to preserve equity capital for technology development and operations.

The collaboration also reflects a long-term commitment between the two companies to develop the financing structures and deployment playbook that orbital compute infrastructure will require to move from the laboratory to low Earth orbit.

"Asset financing didn't invent aviation or shipping, but it accelerated them at scale," said Rob DeMillo, CEO and Cofounder of Sophia Space. "We're doing the same for orbital computing. This approach with SLI signals that Sophia Space's space infrastructure is mature enough to attract the capital structures that have historically built terrestrial infrastructure."

The financing structure, outlined in a non-binding letter of support, aligns SLI's financing with Sophia's build and deployment schedule, supporting the purchase and deployment of 10 Sophia TILE spacecraft through a long-term operating lease. Mission launches are scheduled for as early as 2028.

The constellation is designed to deliver in-orbit edge data services for applications including Earth observation, weather analytics, supply-chain management, and disaster preparedness, while also addressing growing demand for intelligence, surveillance, and reconnaissance (ISR) and other mission-critical security applications.

"Lowering barriers to entry unlocks markets," explained Praveen Vetrivel, Chief Executive Officer at SLI. "Sophia has the technology, the team, and the vision. What had been missing was access to scalable, non-dilutive capital. This framework provides it, giving them the capacity and flexibility they need to build the next layer of digital infrastructure."

The long-term lease is designed to span the satellites' expected useful lives, matching capital deployment with the revenue-generating life of the assets. The approach provides Sophia with a predictable financing structure for scaling its orbital infrastructure without relying exclusively on equity capital.

SLI is the aerospace subsidiary of Libra Group, which brings more than $15 billion in asset financing experience in the transportation industries to the space economy.

About Sophia Space Inc.

Sophia Space is building the future of orbital computing and in-space data centers. Its modular TILE technology enables passive computing alongside in-situ data processing, AI acceleration, and edge computing for satellites, defense systems, and commercial space stations, dramatically reducing latency and delivering actionable insights where and when they are needed. Learn more at www.sophia.space

About SLI

SLI was established by Libra Group in 2023 to address the capital needs of the rapidly growing aerospace industry by providing flexible, innovative asset-financing solutions with an initial focus on satellites, ground stations and frontier aviation assets, such as zero-emission electric aircraft. Leveraging Libra Group companies' decades of experience owning and leasing high-value, mission-critical assets around the world across aviation, maritime, and renewable energy, SLI seeks to bridge the gap between capital availability and asset deployment, accelerating the creation of an integrated aerospace economy. www.sliaerospace.com

SOURCE Sophia Space

Share this article

'Travel China with the Spring Festival Gala' new season captivates audiences with fresh take on urban cultural tourism

YIBIN, China, Sept. 13, 2026 /PRNewswire/ -- "Travel China with the Spring Festival Gala" invites viewers to step into mountains and seas and discover that each city holds a thousand years of history. It is an urban cultural tourism reality show heavily invested in by China Media Group, and its new 2026 season is currently airing. With Spring Festival Gala branch venue cities as its coordinates, the show transforms each city's geographical texture, cultural heritage and modern development into accessible and engaging variety content through live-action competitive games and immersive cultural exploration, making "traveling with the Spring Festival Gala" a new paradigm for cultural tourism integration.

The first stop, Yiwu, showcased the open vitality of the "world's supermarket" through cross-cultural interaction and received widespread praise from audiences. The following chapter, Yibin, built on the unique status of "the first city on the Yangtze River," integrating the three cultural genes of tea, liquor and bamboo with contemporary themes such as new energy and ecological governance. The entire city became a moving live-action arena, translating Yibin's landscape, culture and industrial ambitions into lighthearted variety language. Audiences can see the cultural lineage in the charm of tea, liquor and bamboo, feel the city's new vitality in Yibin's smart manufacturing including power batteries, and understand, amid laughter, the enterprising pulse of this river city as it inherits the past and inspires the future.

"Travel China with the Spring Festival Gala" comes from the Spring Festival Gala stage, transforming one-way city introductions into flowing, two-way co-creation. Rooted in the Spring Festival Gala IP, it has made a city popular and allowed more people to see China's diverse charm. Stay tuned for the next stop and more discoveries.

SOURCE Travel China with the Spring Festival Gala

Share this article

Accro Bioscience Announces Inclusion of AC-101 tablets in the NMPA CDE's "Caring Plan-Extension" Pilot Program for Rare Disease Drug Development

NEW YORK and SUZHOU, China, Sept. 13, 2026 /PRNewswire/ -- On September 14, 2026 (China Standard Time, UTC+8), Accro Bioscience announced that AC-101 tablets have been included in the Rare Diseases Innovative Drug Development Encouragement Pilot Program (the "Caring Plan-Extension", known in Chinese as "关爱计划-延伸" of the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), with Blau syndrome as the proposed indication. The relevant public notice period ended on September 11, 2026. Previously, in June 2026, the U.S. Food and Drug Administration (FDA) granted AC-101 Rare Pediatric Disease (RPD) designation for the treatment of Blau syndrome (BS).

About AC-101

AC-101 is a novel, selective RIPK2 inhibitor derived from Accro Bioscience's proprietary drug discovery platform targeting regulatory cell death and inflammation. It is being developed for the treatment of moderate-to-severe ulcerative colitis (UC). Receptor interacting protein kinase 2 (RIPK2) is a key mediator in the NOD signaling pathway, and dysregulation of NOD/RIPK2 signaling is associated with multiple inflammatory and autoimmune diseases, including inflammatory bowel disease (IBD). AC-101 has completed Phase I studies in healthy volunteers in Australia and China, demonstrating favorable safety and PK/PD profile. A Phase Ib/IIa proof-of-concept study in Chinese patients with moderate-to-severe UC has been completed. The efficacy and safety results from this study will be presented at UEG Week 2026. For details, please see the related press release.

About Blau Syndrome

Blau syndrome is a rare hereditary autoinflammatory disease caused by pathogenic variants in the NOD2 gene. It usually begins in early childhood and can involve multiple systems, including the skin, joints and eyes. Its classic clinical presentation is the triad of granulomatous dermatitis, arthritis and uveitis. Joint involvement may lead to joint deformity and functional impairment over time. Ocular involvement can cause uveitis; if not controlled promptly, it may lead to severe visual impairment or even blindness.[1,2]

About Accro Bioscience

Accro Bioscience Inc. is a clinical-stage biotechnology company pioneering the discovery, development and commercialization of novel therapeutics for inflammatory and autoimmune diseases, by targeting molecular mechanisms of regulatory cell death. The company's robust pipeline of first- and best-in-class compounds offers the potential to bring innovative, paradigm-shifting therapies to patients.

For more information, please visit www.accropeutics.com.

[1]. NIH/NLM MedlinePlus Genetics — Blau syndrome

[2]. NIH/NLM MeSH — Blau syndrome

SOURCE Accro Bioscience (Suzhou) Limited

Share this article

PTK7 Expression Remained Stable Following Standard-of-Care Therapies, Supporting Its Relevance as

a Target in Second- or Later-Line EGFR NSCLC

Findings Reinforce the Scientific Rationale for HWK-007, Whitehawk's Next-Generation PTK7-Directed

ADC Currently in Phase 1 Development

MORRISTOWN, N.J., Sept. 13, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced the presentation of two real-world analyses supporting protein tyrosine kinase 7 (PTK7) as a durable and clinically relevant ADC target in patients with pretreated, EGFR wild-type non-small cell lung cancer (NSCLC). The data will be presented at the IASLC 2026 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, taking place September 12-15, 2026, in Seoul, Republic of Korea.

In tumor samples from patients with EGFR wild-type lung adenocarcinoma, PTK7 expression remained largely stable following standard-of-care (SoC) treatments, including chemotherapy and immunotherapy, and demonstrated less treatment associated variation than several other ADC targets in late-stage development. PTK7 expression was also generally consistent regardless of the presence or absence of other actionable genomic alterations (AGA). These findings indicate PTK7 remains available for targeted ADCs for patients that have progressed through multiple lines of SoC therapy and across clinically relevant subgroups.

A separate analysis of patients with advanced EGFR wild-type lung adenocarcinoma found that real-world overall survival was not impacted based on PTK7-expression, supporting PTK7 as a target-engagement biomarker for ADC payload delivery independent of prognosis in NSCLC.

"The development strategy for our PTK7-directed ADC, HWK-007, is grounded in understanding not only where PTK7 is expressed, but also how that expression behaves in a real-world treatment setting," said Margaret Dugan, MD, Chief Medical Officer of Whitehawk Therapeutics. "The stability of PTK7 expression after standard of care therapies, in particular compared to other therapies in late-stage development, add important translational context as we evaluate HWK-007 in patients with EGFR wild-type NSCLC."

Key Findings:

Durable and Treatment-Agnostic PTK7 Expression in EGFR Wild-Type Lung Adenocarcinoma Supports Targeted ADC Development

- PTK7 expression remained largely stable following standard-of-care immunotherapy, chemotherapy, chemoimmunotherapy and tyrosine kinase inhibitor treatment, suggesting that the target may remain available for PTK7-directed therapy after prior treatment.

- Stable PTK7 expression is also observed in paired tumor samples.

- PTK7 demonstrated less treatment-associated variation than several late-stage ADC targets, including MET, PD-L1 and ITGB6.

- PTK7 expression was generally consistent across tumors with or without other AGA, including KRAS G12C, ALK and MET alterations, suggesting relevance of PTK7 as an ADC target across both AGA+ and AGA- NSCLC subgroups.

Association Between PTK7 Expression and Real-World Survival in Pretreated Patients With EGFR Wild-Type Lung Adenocarcinoma

- PTK7 expression was not independently associated with real-world overall survival or progression-free survival in patients with advanced EGFR wild-type lung adenocarcinoma receiving second- or later-line therapy, supporting PTK7 as a target-engagement biomarker rather than a marker of prognosis.

- Clinical outcomes were driven primarily by established prognostic factors, including Eastern Cooperative Oncology Group performance status and extent of prior therapy.

- PTK7-low tumors were enriched for KEAP1 and STK11 alterations, suggesting biological heterogeneity of EGFR wild-type NSCLC.

"Understanding whether a therapeutic target remains present after prior treatment is particularly important in advanced lung cancer, where patients often receive multiple lines of therapy," said Aaron E. Lisberg, MD, Associate Professor of Medicine at the David Geffen School of Medicine at UCLA. "The stability of PTK7 expression across standard treatments and clinically relevant molecular subgroups supports further investigation of PTK7-directed ADCs in patients with previously treated EGFR wild-type lung adenocarcinoma."

Poster Presentation Details:

Title: Durable and Treatment-Agnostic PTK7 Expression in EGFR Wild-Type Lung Adenocarcinoma Supports Targeted ADC Development

Poster: P2.241

Presenter: Aaron E. Lisberg, MD, University of California Los Angeles, Los Angeles, CA, USA

Date & Time: Monday, September 14, 2026, at 10:30 AM KST

Title: Association Between PTK7 Expression and Real-World Survival in Pretreated Patients With EGFR Wild-Type Lung Adenocarcinoma

Poster: P2.147

Presenter: Grace Dy, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Date & Time: Monday, September 14, 2026, at 10:30 AM KST

HWK‑007 is PTK7-directed, next-generation ADC being evaluated in an ongoing Phase 1 clinical trial in patients with non-squamous, EGFR wild-type NSCLC, platinum-resistant ovarian cancer and endometrial cancer (NCT07444814).

These analyses were conducted as part of a previously announced collaboration between Whitehawk and Tempus AI. The posters will be accessible on the Presentations page of the Investors & News section of the Company's website at www.whitehawktx.com.

About Whitehawk Therapeutics

Whitehawk Therapeutics is a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved cancer treatments. Whitehawk's portfolio includes HWK-007, HWK-016 and HWK-206, ADCs engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement.

Whitehawk's underlying ADC platform leverages CPT113 as the core linker-payload technology, enhanced with its proprietary Carbon Bridge Cysteine Re-pairing (CBCR) bioconjugation process to support improved stability and therapeutic index. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn. Any references to the Company's website or other online resources are provided solely for convenience and are not incorporated by reference into this press release. Investors should rely only on the information contained in this press release and the Company's filings with the Securities and Exchange Commission.

Forward-Looking Statements

This press release contains certain forward-looking statements regarding the business of Whitehawk Therapeutics that are not a description of historical facts within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on the Company's current beliefs and expectations and may include, but are not limited to, statements relating to the potential therapeutic value and market opportunity for HWK-007 and  expectations regarding the beneficial characteristics, design features and the potential targeted markets with respect to HWK-007. Actual results could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, uncertainties associated with preclinical and clinical development of HWK-007 .

Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including under the caption "Item 1A. Risk Factors," and in Whitehawk's subsequent Quarterly Reports on Form 10-Q, and elsewhere in Whitehawk's reports and other documents that Whitehawk has filed, or will file, with the SEC from time to time and available at www.sec.gov.

All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Whitehawk undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This cautionary statement is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contact:

[email protected]

SOURCE Whitehawk Therapeutics, Inc.

Share this article